Clinical Trials Logo

Clinical Trial Summary

This project studies how 2-deoxy-glucose (2DG) pills are absorbed and distributed in people with epilepsy. 2DG is similar to glucose, the main energy source for the brain, but it cannot be used as energy. During seizures, neurons are at a very high metabolic state with huge glucose metabolism as glycolysis is accelerated to supply the high metabolic needs of a seizure. 2DG is taken up by cells but cannot be metabolized by the first enzyme in the glycolytic pathway, thus is stops, or "clogs up", glycolysis. Since brain metabolism is almost entirely dependent on glucose as an energy source, glycolysis is arrested and may stop seizures. It is hoped that 2DG will stop seizures by interfering with the brain's energy use. This is an open-label phase 2 study of the pharmacokinetics (PK), safety, and tolerability of 2DG administered orally to adult epilepsy patients. A 3-level 2DG dose escalation is planned in sequential cohorts of 3 subjects in each cohort with review of each cohort before proceeding to the next cohort. On the day of oral 2DG exposure, subjects will receive a single dose of 40 mg in the first cohort, a single dose of 60 mg in the second cohort, and two 60 mg doses (60 mg bid) in the third cohort. After 3 subjects have completed dosing at Dose Level 1 (40 mg/day), the safety and PK results will be reviewed. The Study Committee will determine if the next cohort should be enrolled at Dose Level 2 (60 mg/day). The same procedure will be repeated to determine if the next cohort should be enrolled at Dose Level 3 (60 mg bid = 120 mg/day). If the Study Committee determines that the most recent dose is not tolerated or that there are significant adverse events, the subsequent Dose Level will not be enrolled. A standard time-concentration curve will be constructed from the 2DG levels obtained from the PK blood draws. Parameters will be calculated for: time to maximum concentration (tmax), maximum concentration (Cmax), elimination rate, half-life (t1/2), AUC, and derived parameters. Statistical analysis will not be performed because of the small n, but this will nevertheless establish the PK profile of 2DG in people with epilepsy. The most important parameter will be the AUC which determines drug exposure.


Clinical Trial Description

The study will be conducted as a 1-day Monitored Dosing and Pharmacokinetics Period in an inpatient setting. Subjects will report to the hospital in a fasted state (since midnight) on the morning of the pharmacokinetics study. Subjects will continue to fast until one hour after the 2DG dose has been given. 2DG will be given as either a single oral dose (40 mg for Dose Level 1; 60 mg for dose level 2) or 60 mg bid (Dose Level 3). Blood for pharmacokinetic analysis will be drawn at time 0 (prior to drug administration), and then at 15, 30, 45, and 60 minutes and at 2, 4, 6, 12, and 24 hours after single dose 2DG administration. Blood for pharmacokinetic analysis will be drawn at time 0 (prior to drug administration) and then at 15, 30, 45, and 60 minutes and at 2, 4, 6, 12, and 24 hours after the last dose for Dose Level 3. Patients will be closely monitored for safety during and following dosing with 2DG. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05605301
Study type Interventional
Source University of Virginia
Contact
Status Completed
Phase Phase 2
Start date September 2, 2022
Completion date February 5, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03548779 - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 N/A
Completed NCT05257811 - Earbud EEG Feasibility Study
Completed NCT05066880 - Yoga and Aerobic Exercise in Epilepsy N/A
Recruiting NCT06278428 - Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age
Terminated NCT04639310 - XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy Phase 3
Withdrawn NCT04737174 - ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Tumors Phase 2
Not yet recruiting NCT06275685 - Forecasting Seizures Using Intelligent Wearable Technology for Health Tracking N/A
Completed NCT04822662 - The Individual and Family Self Management Theory Based Epilepsy Education Program's Effectiveness N/A
Recruiting NCT04759196 - Generating Evidence on NonEpileptic, Stereotypical and Intermittent Symptoms (NESIS) in Chronic Subdural Hematomas Phase 4
Completed NCT04171934 - Clinical Validation of a Video-based Epilepsy Examination Service
Recruiting NCT04569708 - Sleep Spindles and Memory in Rolandic Epilepsy N/A
Completed NCT04311151 - Impact of Self-visualization of Epileptic Seizures on Patients' Perception of the Disease and Risk Behavior N/A
Not yet recruiting NCT05635396 - Seizures Detection in Real Life Setting N/A
Completed NCT05675254 - The Prevalence and Risk Factors of Coagulopathy in Pediatric Epilepsy Surgery Patients
Terminated NCT04912856 - An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE Phase 3
Recruiting NCT04221282 - ZEBinix® Retention Rate in Epilepsy in Elderly Patients